



Docket No. QED0003

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Victor V. GOGOLAK

Group Art Unit: 2166

Serial No.: 09/681,586

Examiner: To Be Assigned

Filed: May 2, 2001

For: METHOD FOR GRAPHICALLY DEPICTING DRUG ADVERSE EFFECT RISKS

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Commissioner of Patents
Washington, D.C. 20231

RECEIVED

SEP 12 2002

GROUP 3000

Sir:

In accordance with the requirements of 37 C.F.R. §§ 1.56, 1.97-1.98 and MPEP § 609, the references noted on the attached Form PTO-1449 are hereby brought to the attention of the Examiner.

No fees are believed to be necessary since the references cited in this statement are being submitted before the First Office Action or were cited by a foreign patent office in a counterpart foreign application not more than three months prior to this submission.

However, the Commissioner is hereby authorized to charge any additional fees which may be required, or to credit any overpayment, to Deposit Account No. 501458. A duplicate copy of this letter is submitted herewith for that purpose.

The above information is presented so that the United States Patent and Trademark Office may, in the first instance, determine any materiality thereof to the claimed invention. See 37 C.F.R. §§ 1.104(a) and 1.106(b) conferring the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

Respectfully submitted,

Date: _____

9/6/02

By: _____

George T. Marcou
Registration No. 33,014

KILPATRICK STOCKTON LLP
Suite 900
607 14th Street, N.W.
Washington, D.C. 20005
(202) 508-5800

47302/259353
WSHLIB01:127406